ArticleThoracic cancer2018
Hyperprogressive disease in patients with non-small cell lung cancer treated with nivolumab: A case series.
Article in Thoracic cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Risk factors for pulmonary infection in patients with non-small cell lung cancer: a Meta-analysis.BMC pulmonary medicine · 2024Pooled it
- Hyperprogression of brain metastases following initiation of immune checkpoint inhibitors.Journal of neuro-oncology · 2025Article
- [Advances in Pseudoprogression of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Prognostic Factors and Markers in Non-Small Cell Lung Cancer: Recent Progress and Future Challenges.Genes · 2023Review
- Hyperprogressive disease in non-small cell lung cancer after PD-1/PD-L1 inhibitors immunotherapy: underlying killer.Frontiers in immunology · 2023Review
- Tumor Cell-Intrinsic BTLA Receptor Inhibits the Proliferation of Tumor Cells via ERK1/2.Cells · 2022Article
- Review
- Hyperprogressive Disease in Malignant Carcinoma With Immune Checkpoint Inhibitor Use: A Review.Frontiers in nutrition · 2022Review
- Mechanism underlying the immune checkpoint inhibitor-induced hyper-progressive state of cancer.Cancer drug resistance (Alhambra, Calif.) · 2022Review
- Successful Re-administration of Atezolizumab for a Non-small-cell Lung Cancer Patient after Cardiac Tamponade Development as a Manifestation of Pseudo-progression Induced by Combination Treatment with Atezolizumab and Cytotoxic Chemotherapy.Internal medicine (Tokyo, Japan) · 2021Article
- Article
- Expectoration of tonsillar metastasis of pulmonary pleomorphic carcinoma after pseudoprogression: A case report.Thoracic cancer · 2021Article
- The genomic characteristics of different progression patterns in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors.Annals of translational medicine · 2021Article
- Potentials of Non-InvasiveFrontiers in genetics · 2021Review
- Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.Frontiers in pharmacology · 2021Review
- Pseudoprogression and hyperprogression in lung cancer: a comprehensive review of literature.Journal of cancer research and clinical oncology · 2020Review
- Hyperprogression: A novel response pattern under immunotherapy.Clinical and translational medicine · 2020Review
- Hyperprogressive Disease upon Immune Checkpoint Blockade: Focus on Non-small Cell Lung Cancer.Current oncology reports · 2020Review
- Article
- Tumor intrinsic immunity related proteins may be novel tumor suppressors in some types of cancer.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNivolumab is an anti-PD-1 blocking monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). However, some patients on immunotherapy may experience rapid progression and worsening clinical status, known as hyperprogressive disease. We retrospectively reviewed the clinical records of patients with NSCLC administered nivolumab therapy at Toneyama National Hospital, Japan, from January 2016 to January 2018. Of the 87 patients administered nivolumab therapy, five experienced rapid progression during one cycle of nivolumab therapy. Four patients were treated with corticosteroids to overcome their symptomatic events. Nivolumab exhibited efficacy after temporal progression, so-called "pseudoprogression", in three patients, and their symptoms and laboratory results improved. In the other patient, pleural and pericardial effusions increased after nivolumab therapy, and drainage was required, with no subsequent recurrence. The clinical courses of our case series indicate that alternative treatment, namely high-dose corticosteroids, antibiotics, and drainage, effectively treated the symptoms of rapid tumor progression. Of note, corticosteroids suppressed the temporary inflammatory reaction to nivolumab. Although hyperprogressive disease is thought to be associated with poor quality of life and survival, these treatment strategies may be useful in patients with expected responses to immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.